MAP2K7 and thyroid tumor: Normally, activation of a tyrosine kinase leads to a cascade of sequential phosphorylation of RAS, BRAF, MEK and then MAPK, so the MAPK/ERK pathways inhibitors have become an important target for thyroid tumors treatment [19, 20].